Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02131597 · ClinicalTrials.gov registry record · Phase 2
Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT02131597: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT02131597 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02131597, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
This phase II trial studies how well guadecitabine works in treating patients with myelodysplastic syndromes that are at higher risk for becoming acute myeloid leukemia. Guadecitabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Guadecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2014-11-10 |
| Est. Completion | 2024-07-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02131597
The ClinicalTrials.gov registry entry for NCT02131597 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Guadecitabine is the first listed.
NCT02131597 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02131597 about?
NCT02131597 is a clinical study titled "Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes". This phase II trial studies how well guadecitabine works in treating patients with myelodysplastic syndromes that are at higher risk for becoming acute myeloid leukemia. Guadecitabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT02131597?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2014-11-10. Estimated completion is 2024-07-25.
What interventions are being tested in trial NCT02131597?
The interventions under investigation include: Guadecitabine (DRUG).
Who is sponsoring clinical trial NCT02131597?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.